CureVac granted patent for its manufacturing process to produce RNA

CureVac molecules image
Germany-based CureVac was granted a patent by the U.S. Patent and Trademark Office for its manufacturing process for producing RNA. (CureVac)

CureVac, a biopharmaceutical maker focused on mRNA-based drugs, was granted a patent by the U.S. Patent and Trademark Office for its manufacturing process for producing RNA.

The company said it is the first in its field to get a patent for the entire manufacturing process of in vitro transcribed RNA. The patent covers processes for the in vitro transcription of template DNA including proprietary quality control steps for producing purified RNA.

The company's technology works by delivering antigen-encoding mRNA molecules to the body to induce both cellular and humoral immune responses.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“Our highest priority has always been to create ultra-pure mRNA at the lowest cost of goods,” Ingmar Hoerr, CureVac’s co-founder and CEO, said in a statement. “Based on our extensive know-how and IP, we are currently building our industrial-scale production facility designed to produce up to 30 million doses of RNA-based therapeutics per year.”

In February, CureVac received two new grants from the Bill & Melinda Gates Foundation. The foundation had previously given the company a $52 million equity investment.

CureVac has been working on developing a seasonal flu vaccine using its technology. Dubbed CV7302, the flu shot is slated to enter human testing this year. The Gates grant, however, is focused on a universal flu vaccine.

The Germany-based company is also eying a potential $1.8 billion deal with Eli Lilly to develop five mRNA cancer vaccines, and it is collaborating with Boehringer Ingelheim in non-small cell lung cancer.

Suggested Articles

Alvogen is recalling two lots of mismarked fentanyl patches because they could lead to overdoses.

The recall from the U.S. of tainted blood pressure medicines reached new heights as India’s Torrent Pharmaceuticals recalled 104 lots of losartan.

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.